SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-κB and ERK Signaling

Kim, Dong Hwi; Yong, Hyo Jeong; Mander, Sunam; Nguyen, Huyen Thi; Nguyen, Lan Phuong; Park, Hee Kyung; Kyeong, Hyo; Kim, Won Ki; Hwang, Jong Ik

doi:10.4062/biomolther.2020.200

Cited by 5 publications

(5 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 20 Thus, anticancer drugs effectively increase the expression of p53 by which mechanism related to inhibition of anti-apoptotic protein (Bcl-2) expression to delay tumorigenesis in BaP-induced colorectal cancer. 21 Furthermore, it is co-regulated with targets of NF-κB in tumor-associated macrophages and can drive pro-inflammatory cytokine induction, 22 such as that of IL-6 and TNF-α. NF-κB activation enhances cancer cell proliferation, and survival β-catenin regulates NF-κB activity in primary colorectal cancers 23 as a pro-transcription activator.…”

Section: Discussionmentioning

confidence: 99%

The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days

Zheng

Park

Kwon³

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

Background Benzo(a)pyrene (BaP) is a carcinogenic compound in contaminated foodstuffs. The effect of oral intake of the environmental carcinogen BaP under low doses and frequent exposure on a digestive system has not been thoroughly verified. Methods In this regard, this study was conducted to prove the toxicity effects of BaP on the stomach and colon tissue after exposure to C57BL/6 mouse (3 and 6 µg/kg) following daily oral administration for 60 days. This study investigated acute gastric mucosal injury, severe gastric edema, cell infiltration, and mononuclear cells, multifocal cells, and tumoral inflammatory cells. Results The results of ELISA showed that the expression of serum interleukin (IL)-6 and tumor necrosis factor-α in the BaP exposure group were significantly increased, and a high level of DNA adduct distribution in their stomach and colon. Moreover, this study has confirmed the expression of early carcinogenesis markers: nuclear factor (NF)-κB, p53, IL-6, superoxide dismutase 1 (SOD1), mucin (MUC1 and MUC2), and β-catenin in the stomach and colon, and showed that there was a significant increase in IL-6, NF-κB, SOD1, β-catenin, and MUC1 ( P < 0.05). At the same time, there was a significant decrease in MUC2 and p53 ( P < 0.05). Thus, even in low doses, oral intake of BaP can induce DNA damage, increasing the potential risk of gastrointestinal cancer. Conclusion This study will provide a scientific basis for researching environmental contaminated food and intestinal health following daily oral administration of BaP.

show abstract

Section: Discussionmentioning

confidence: 99%

The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days

Zheng

Park

Kwon³

et al. 2022

J Korean Med Sci

View full text Add to dashboard Cite

show abstract

“…MMP9 and urokinase plasminogen activator protein are reduced by 10 μM of SP-8356 as determined by zymography assay (Kim et al, 2021;Mander et al, 2019). The effects of SP-8356 on the levels…”

Section: Verbenonementioning

confidence: 99%

“…The administration of SP‐8356 to breast cancer cell lines decreases the gene–gene transcription of proteins associated with migration and invasion, namely MMP2, MMP7, and MMP9. MMP9 and urokinase plasminogen activator protein are reduced by 10 μM of SP‐8356 as determined by zymography assay (Kim et al, 2021; Mander et al, 2019). The effects of SP‐8356 on the levels of NF‐κB‐target genes, which affect cell adhesion, local invasion, and angiogenesis, were examined.…”

Section: Monoterpenoids Modulating Metastatic Pathwaymentioning

confidence: 99%

Monoterpenoids: An upcoming class of therapeutic agents for modulating cancer metastasis

Mathur,

Meena,

Luqman

2023

Phytotherapy Research

View full text Add to dashboard Cite

Monoterpenoids, a sub‐class of terpenoids, are secondary metabolites frequently extracted from the essential oils of aromatic plants. Their antitumor properties including antiproliferative, apoptotic, antiangiogenic, and antimetastatic effects along with other biological activities have been the subject of extensive study due to their diverse characteristics. In recent years, numerous investigations have been conducted to understand its potential anticancer impacts, specifically focusing on antiproliferative and apoptotic mechanisms. Metastasis, a malignancy hallmark, can exert either protective or destructive influences on tumor cells. Despite this, the potential antimetastatic and antiangiogenic attributes of monoterpenoids need further exploration. This review focuses on specific monoterpenoids, examining their effects on metastasis and relevant signaling pathways. The monoterpenoids exhibit a high level of complexity as natural products that regulate metastatic proteins through various signaling pathways, including phosphoinositide 3‐kinase/protein kinase B/mammalian target of rapamycin, mitogen‐activated protein kinase/extracellular signal‐regulated kinase/jun N‐terminal kinase, nuclear factor kappa B, vascular endothelial growth factor, and epithelial mesenchymal transition process. Additionally, this review delves into the biosynthesis and classification of monoterpenoids, their potential antitumor impacts on cell lines, the plant sources of monoterpenoids, and the current status of limited clinical trials investigating their efficacy against cancer. Moreover, monoterpenoids depict promising potential in preventing cancer metastasis, however, inadequate clinical trials limit their drug usage. State‐of‐the‐art techniques and technologies are being employed to overcome the challenges of utilizing monoterpenoids as an anticancer agent.

show abstract

“…The betulinic acid administration has been associated with inhibition of NF‐κB signaling and subsequent downregulation of VASP in reducing proliferation and metastasis of gastric tumor cells (Chen et al, 2020). Overall, the antitumor agents have a capacity of reducing tumor progression via inhibiting NF‐κB signaling (M. Chen et al, 2021; D. H. Kim et al, 2021; Y. C. Liu, Huang et al, 2021; Manu et al, 2014, 2015; Ramadass et al, 2020; Shanmugam, Ahn, Hsu et al, 2018). Thus, NF‐κB signaling inhibition by antitumor agents not only impairs the proliferation and metastasis of cancer cells but also enhances antitumor immunity (Zeng et al, 2021).…”

Section: Role Of Nf‐κb In Different Malignanciesmentioning

confidence: 99%

“…The betulinic acid administration has been associated with inhibition of NF-κB signaling and subsequent downregulation of VASP in reducing proliferation and metastasis of gastric tumor cells . Overall, the antitumor agents have a capacity of reducing tumor progression via inhibiting NF-κB signaling (M. D. H. Kim et al, 2021;Y.…”

Section: Role Of Nf-κb In Different Malignanciesmentioning

confidence: 99%

NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition

Mirzaei

Saghari

Bassiri

et al. 2022

Journal Cellular Physiology

104

View full text Add to dashboard Cite

Metastasis of tumor cells is a complex challenge and significantly diminishes the overall survival and prognosis of cancer patients. The epithelial‐to‐mesenchymal transition (EMT) is a well‐known mechanism responsible for the invasiveness of tumor cells. A number of molecular pathways can regulate the EMT mechanism in cancer cells and nuclear factor‐kappaB (NF‐κB) is one of them. The nuclear translocation of NF‐κB p65 can induce the transcription of several genes involved in EMT induction. The present review describes NF‐κB and EMT interaction in cancer cells and their association in cancer progression. Due to the oncogenic role NF‐κB signaling, its activation enhances metastasis of tumor cells via EMT induction. This has been confirmed in various cancers including brain, breast, lung and gastric cancers, among others. The ZEB1/2, transforming growth factor‐β, and Slug as inducers of EMT undergo upregulation by NF‐κB to promote metastasis of tumor cells. After EMT induction driven by NF‐κB, a significant decrease occurs in E‐cadherin levels, while N‐cadherin and vimentin levels undergo an increase. The noncoding RNAs can potentially also function as upstream mediators and modulate NF‐κB/EMT axis in cancers. Moreover, NF‐κB/EMT axis is involved in mediating drug resistance in tumor cells. Thus, suppressing NF‐κB/EMT axis can also promote the sensitivity of cancer cells to chemotherapeutic agents.

show abstract

SP-8356, a (1S)-(-)-Verbenone Derivative, Inhibits the Growth and Motility of Liver Cancer Cells by Regulating NF-κB and ERK Signaling

Cited by 5 publications

References 45 publications

The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days

The Risk of Gastrointestinal Cancer on Daily Intake of Low-Dose BaP in C57BL/6 for 60 Days

Monoterpenoids: An upcoming class of therapeutic agents for modulating cancer metastasis

NF‐κB as a regulator of cancer metastasis and therapy response: A focus on epithelial–mesenchymal transition

Contact Info

Product

Resources

About